Abstract
Background: Voriconazole (VRZ) is widely used for fungal keratitis topically. It is sparingly water soluble and has limited permeability which can lead to poor bioavailability. Nanostructured Lipid Carriers (NLCs) are selected as a carrier for voriconazole as they increase solubility while the lipidic character of the formulation facilitates permeation.
Objectives:
• To develop a new method of preparation of lipidic nanoparticles
• To apply Quality by design and risk-based approach to find variables
• To optimize variables and find the design space
• To evaluate and characterize the optimized formulation
Methods: The present study is an attempt to address the challenges in the formulation of NLCs using a high-speed homogenizer. Quality by Design approach was used to find the material attributes and process parameters playing a significant role in the formulation development. Quality Target product profile was prepared, and failure mode and effect analysis was performed for a better understanding of the risks, ways to alleviate risks, and finally, to propose a control strategy. The formulation was optimized by using 3-levels 3-factors central composite design, and design space was obtained by using graphical optimization. The morphology of the particles was studied by using Transmission Electron Microscope. In vitro drug release study was performed using Franz diffusion cell.
Results: The amount of solid lipid, solid lipid to total lipid ratio, and concentration of surfactant were found to be high risk variables and their effects on the product quality were examined using Central composite design considering particle size, particle size distribution and %entrapment efficiency as dependent variables. Optimized NLC had a particle size of 72.58 nm with PDI 0.137 and %entrapment efficiency of 78.79%. The in vitro drug release study showed sustained drug release over the period of 24 hrs and followed the Higuchi model with a fickian diffusion mechanism.
Conclusion: The present study successfully explored QbD along with Risk-based approach for the development of voriconazole containing lipidic nanoparticles.
Graphical Abstract
[1]
Bourcier T, Sauer A, Dory A, Denis J, Sabou M. Fungal keratitis. J Fr Ophtalmol 2017; 40(9): e307-13.
[http://dx.doi.org/10.1016/j.jfo.2017.08.001] [PMID: 28987448]
[http://dx.doi.org/10.1016/j.jfo.2017.08.001] [PMID: 28987448]
[2]
Ahn M, Yoon KC, Ryu SK, Cho NC, You IC. Clinical aspects and prognosis of mixed microbial (bacterial and fungal) keratitis. Cornea 2011; 30(4): 409-13.
[3]
Al-Badriyeh D, Neoh CF, Stewart K, Kong DC. Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis. Clin Ophthalmol 2010; 4(4): 391-405.
[PMID: 20463910]
[PMID: 20463910]
[4]
Manzouri B, Wyse RKH, Vafidis GC. Pharmacotherapy of fungal eye infections. Expert Opin Pharmacother 2001; 2(11): 1849-57.
[http://dx.doi.org/10.1517/14656566.2.11.1849] [PMID: 11825321]
[http://dx.doi.org/10.1517/14656566.2.11.1849] [PMID: 11825321]
[5]
Müller GG, Kara-José N, de Castro RS. Antifungals in eye infections: Drugs and routes of administration. 2013.
[6]
Murphy M, Bernard EM, Ishimaru T, Armstrong D. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997; 41(3): 696-8.
[http://dx.doi.org/10.1128/AAC.41.3.696] [PMID: 9056016]
[http://dx.doi.org/10.1128/AAC.41.3.696] [PMID: 9056016]
[7]
Siafaka P, Üstündağ Okur N, Mone M, et al. Two different approaches for oral administration of voriconazole loaded formulations: electrospun fibers versus β-cyclodextrin complexes. Int J Mol Sci 2016; 17(3): 282.
[http://dx.doi.org/10.3390/ijms17030282] [PMID: 26927072]
[http://dx.doi.org/10.3390/ijms17030282] [PMID: 26927072]
[8]
Siafaka PI, Titopoulou A, Koukaras EN, et al. Chitosan derivatives as effective nanocarriers for ocular release of timolol drug. Int J Pharm 2015; 495(1): 249-64.
[http://dx.doi.org/10.1016/j.ijpharm.2015.08.100] [PMID: 26341322]
[http://dx.doi.org/10.1016/j.ijpharm.2015.08.100] [PMID: 26341322]
[9]
Gan L, Wang J, Jiang M, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today 2013; 18(5-6): 290-7.
[http://dx.doi.org/10.1016/j.drudis.2012.10.005] [PMID: 23092895]
[http://dx.doi.org/10.1016/j.drudis.2012.10.005] [PMID: 23092895]
[10]
Sánchez-lópez E, Espina M, Doktorovova S, Souto EB, García ML. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part II - Ocular drug-loaded lipid nanoparticles. Eur J Pharm Biopharm 2017; 110: 58-69.
[http://dx.doi.org/10.1016/j.ejpb.2016.10.013]
[http://dx.doi.org/10.1016/j.ejpb.2016.10.013]
[11]
Siafaka PI, Çağlar EŞ, Sipahi H, Charehsaz M, Aydın A, Üstündağ Okur N. Ocular microemulsion of brinzolamide: Formulation, physico-chemical characterization, and in vitro irritation studies based on EpiOcular™ eye irritation assay. Pharm Dev Technol 2021; 26(7): 765-78.
[http://dx.doi.org/10.1080/10837450.2021.1944206] [PMID: 34154503]
[http://dx.doi.org/10.1080/10837450.2021.1944206] [PMID: 34154503]
[12]
Khare A, Singh I, Pawar P, Grover K. Design and evaluation of voriconazole loaded solid lipid nanoparticles for ophthalmic application. J Drug Deliv 2016; 2016: 1-11.
[http://dx.doi.org/10.1155/2016/6590361] [PMID: 27293896]
[http://dx.doi.org/10.1155/2016/6590361] [PMID: 27293896]
[13]
Zhao N, Zhang J, Luo Q, Yang J, Xu H, et al. Sorafenib-loaded nanostructured lipid carriers for topical ocular therapy of corneal neovascularization: development, in-vitro and in vivo study. Drug Deliv 2022; 29(1): 837-55.
[http://dx.doi.org/10.1080/10717544.2022.2048134]
[http://dx.doi.org/10.1080/10717544.2022.2048134]
[14]
Füredi P, Pápay ZE, Kovács K, et al. Development and characterization of the voriconazole loaded lipid-based nanoparticles. J Pharm Biomed Anal 2017; 132(132): 184-9.
[http://dx.doi.org/10.1016/j.jpba.2016.09.047] [PMID: 27750101]
[http://dx.doi.org/10.1016/j.jpba.2016.09.047] [PMID: 27750101]
[15]
Javed MN, Kohli K, Amin S. Risk assessment integrated QbD approach for development of optimized bicontinuous mucoadhesive limicubes for oral delivery of Rosuvastatin. AAPS PharmSciTech 2018; 19(3): 1377-91.
[http://dx.doi.org/10.1208/s12249-018-0951-1] [PMID: 29388027]
[http://dx.doi.org/10.1208/s12249-018-0951-1] [PMID: 29388027]
[16]
Garg NK, Sharma G, Singh B, Nirbhavane P, Tyagi RK, Shukla R, et al. Quality by design (qbd)-enabled development of aceclofenac loaded-nano structured lipid carriers (nlcs): An improved dermatokinetic profile for inflammatory disorder(s). Int J Pharm 2016; 517(1-2): 413-31.
[http://dx.doi.org/10.1016/j.ijpharm.2016.12.010] [PMID: 27956192]
[http://dx.doi.org/10.1016/j.ijpharm.2016.12.010] [PMID: 27956192]
[17]
Vohra AM, Patel CV, Kumar P, Thakkar HP. Development of dual drug loaded solid self microemulsifying drug delivery system: Exploring interfacial interactions using QbD coupled risk based approach. J Mol Liq 2017; 242: 1156-68.
[http://dx.doi.org/10.1016/j.molliq.2017.08.002]
[http://dx.doi.org/10.1016/j.molliq.2017.08.002]
[18]
Lee SL, O’Connor TF, Yang X, et al. Modernizing pharmaceutical manufacturing: from batch to continuous production. J Pharm Innov 2015; 10(3): 191-9.
[http://dx.doi.org/10.1007/s12247-015-9215-8]
[http://dx.doi.org/10.1007/s12247-015-9215-8]
[19]
Gurumukhi VC, Bari SB. Fabrication of efavirenz loaded nano-formulation using quality by design (QbD) based approach: Exploring characterizations and in vivo safety. J Drug Deliv Sci Technol 2020; 56(1): 101545.
[http://dx.doi.org/10.1016/j.jddst.2020.101545]
[http://dx.doi.org/10.1016/j.jddst.2020.101545]
[20]
Verma S, Lan Y, Gokhale R, Burgess DJ. Quality by design approach to understand the process of nanosuspension preparation. Int J Pharm 2009; 377(1-2): 185-98.
[http://dx.doi.org/10.1016/j.ijpharm.2009.05.006] [PMID: 19446617]
[http://dx.doi.org/10.1016/j.ijpharm.2009.05.006] [PMID: 19446617]
[21]
Wang F, Chen L, Jiang S, et al. Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box-Behnken design. J Liposome Res 2014; 24(3): 171-81.
[http://dx.doi.org/10.3109/08982104.2014.891231] [PMID: 24611687]
[http://dx.doi.org/10.3109/08982104.2014.891231] [PMID: 24611687]
[22]
Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: A novel drug targeting carrier. J Drug Deliv Sci Technol 2019; 51: 255-67.
[http://dx.doi.org/10.1016/j.jddst.2019.02.017]
[http://dx.doi.org/10.1016/j.jddst.2019.02.017]
[23]
Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine 2016; 12(1): 143-61.
[http://dx.doi.org/10.1016/j.nano.2015.09.004] [PMID: 26410277]
[http://dx.doi.org/10.1016/j.nano.2015.09.004] [PMID: 26410277]
[24]
Sánchez-López E, Espina M, Doktorovova S, Souto EB, García ML. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part I - Barriers and determining factors in ocular delivery. Eur J Pharm Biopharm 2017; 110: 70-5.
[http://dx.doi.org/10.1016/j.ejpb.2016.10.009] [PMID: 27789358]
[http://dx.doi.org/10.1016/j.ejpb.2016.10.009] [PMID: 27789358]
[25]
Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: Recent advances in drug delivery. J Drug Target 2012; 20(10): 813-30.
[http://dx.doi.org/10.3109/1061186X.2012.716845] [PMID: 22931500]
[http://dx.doi.org/10.3109/1061186X.2012.716845] [PMID: 22931500]
[26]
Muchow M, Maincent P, Müller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 2008; 34(12): 1394-405.
[http://dx.doi.org/10.1080/03639040802130061] [PMID: 18665980]
[http://dx.doi.org/10.1080/03639040802130061] [PMID: 18665980]
[27]
Srinubabu G, Raju CAI, Sarath N, Kumar PK, Rao JVLNS. Development and validation of a HPLC method for the determination of voriconazole in pharmaceutical formulation using an experimental design. Talanta 2007; 71(3): 1424-9.
[http://dx.doi.org/10.1016/j.talanta.2006.04.042] [PMID: 19071468]
[http://dx.doi.org/10.1016/j.talanta.2006.04.042] [PMID: 19071468]
[28]
Damle MC, Mehendre R, Khetre AB, Sinha PK. Development and validation of stability indicating RP-HPLC method for voriconazole. Indian J Pharm Sci 2009; 71(5): 509-14.
[http://dx.doi.org/10.4103/0250-474X.58178] [PMID: 20502568]
[http://dx.doi.org/10.4103/0250-474X.58178] [PMID: 20502568]
[29]
Kakade P, Gite S, Patravale V. Development of atovaquone nanosuspension: quality by design approach. Curr Drug Deliv 2020; 17(2): 112-25.
[http://dx.doi.org/10.2174/1567201817666191227095019] [PMID: 31880260]
[http://dx.doi.org/10.2174/1567201817666191227095019] [PMID: 31880260]
[30]
Beg S, Akhter S, Rahman M, Rahman Z. Perspectives of quality by design approach in nanomedicines development. Curr Nanomed 2017; 7: 191-7.
[31]
Thakkar H, Desai J, Parmar M. Application of Box-Behnken design for optimization of formulation parameters for nanostructured lipid carriers of candesartan cilexetil. Asian J Pharm 2014; 8(2): 81-9.
[http://dx.doi.org/10.4103/0973-8398.134921]
[http://dx.doi.org/10.4103/0973-8398.134921]
[32]
Kaithwas V, Dora CP, Kushwah V, Jain S. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability. Colloids Surf B Biointerfaces 2017; 154(154): 10-20.
[http://dx.doi.org/10.1016/j.colsurfb.2017.03.006] [PMID: 28284054]
[http://dx.doi.org/10.1016/j.colsurfb.2017.03.006] [PMID: 28284054]
[33]
Rathod VR, Shah DA, Dave RH. Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: Preformulation screening studies and statistical hybrid-design for optimization of variables. Drug Dev Ind Pharm 2020; 46(3): 443-55.
[http://dx.doi.org/10.1080/03639045.2020.1724135] [PMID: 32037896]
[http://dx.doi.org/10.1080/03639045.2020.1724135] [PMID: 32037896]
[34]
Vora C, Patadia R, Mittal K, Mashru R. Risk based approach for design and optimization of site specific delivery of isoniazid. J Pharm Investig 2015; 45(2): 249-64.
[http://dx.doi.org/10.1007/s40005-014-0170-z]
[http://dx.doi.org/10.1007/s40005-014-0170-z]
[35]
Zhou YZ, Alany RG, Chuang V, Wen J. Optimization of PLGA nanoparticles formulation containing L-DOPA by applying the central composite design. Drug Dev Ind Pharm 2013; 39(2): 321-30.
[http://dx.doi.org/10.3109/03639045.2012.681054] [PMID: 22607101]
[http://dx.doi.org/10.3109/03639045.2012.681054] [PMID: 22607101]
[36]
Goren AY, Recepoğlu YK, Khataee A. Chapter 4 - Language of response surface methodology as an experimental strategy for electro-chemical wastewater treatment process optimization. Cognitive Data Science in Sustainable Computing, Artificial Intelligence and Data Science in Environmental Sensing. Cambridge, USA: Academic Press 2022; pp. 57-92.
[37]
Oktay AN, Karakucuk A, Ilbasmis-Tamer S, Celebi N. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation. Eur J Pharm Sci 2018; 122(122): 254-63.
[http://dx.doi.org/10.1016/j.ejps.2018.07.009] [PMID: 29981401]
[http://dx.doi.org/10.1016/j.ejps.2018.07.009] [PMID: 29981401]
[38]
Antony J. 4 - A Systematic Methodology for Design of Experiments Antony JBT-D of E for E and S. Oxford: Elsevier 2014; pp. 33-50.
[http://dx.doi.org/10.1016/B978-0-08-099417-8.00004-3]
[http://dx.doi.org/10.1016/B978-0-08-099417-8.00004-3]
[39]
Dahiya M, Dureja H. Central composite designed imatinib-loaded magnetic nanoparticles. Curr Nanomed 2016; 6(2): 146-55.
[http://dx.doi.org/10.2174/2468187306666160802125718]
[http://dx.doi.org/10.2174/2468187306666160802125718]
[40]
Jain K, Sood S, Gowthamarajan K. Optimization of artemether-loaded NLC for intranasal delivery using central composite design. Drug Deliv 2014; 7544: 1-15.
[PMID: 24512368]
[PMID: 24512368]
[41]
Shah B, Khunt D, Bhatt H, Misra M, Padh H. Intranasal delivery of venlafaxine loaded nanostructured lipid carrier: Risk assessment and QbD based optimization. J Drug Deliv Sci Technol 2016; 33: 37-50.
[http://dx.doi.org/10.1016/j.jddst.2016.03.008]
[http://dx.doi.org/10.1016/j.jddst.2016.03.008]
[42]
Mandpe L, Pokharkar V. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement. Pharm Dev Technol 2015; 20(3): 320-9.
[http://dx.doi.org/10.3109/10837450.2013.867445] [PMID: 24328553]
[http://dx.doi.org/10.3109/10837450.2013.867445] [PMID: 24328553]
[43]
Ferreira M, Chaves LL, Lima SAC, Reis S. Optimization of nanostructured lipid carriers loaded with methotrexate: A tool for inflammatory and cancer therapy. Int J Pharm 2015; 492(1-2): 65-72.
[http://dx.doi.org/10.1016/j.ijpharm.2015.07.013] [PMID: 26169145]
[http://dx.doi.org/10.1016/j.ijpharm.2015.07.013] [PMID: 26169145]
[44]
Abdelbary G, Fahmy RH. Diazepam-loaded solid lipid nanoparticles: Design and characterization. AAPS PharmSciTech 2009; 10(1): 211-9.
[http://dx.doi.org/10.1208/s12249-009-9197-2] [PMID: 19277870]
[http://dx.doi.org/10.1208/s12249-009-9197-2] [PMID: 19277870]
[45]
Shaal L. Preserving hesperetin nanosuspensions for dermal application. Die Pharm - An Int. J Pharm Sci 2010; 65(86): 92-117.
[46]
Bajaj A, Rao MRP, Pardeshi A, Sali D. Nanocrystallization by evaporative antisolvent technique for solubility and bioavailability enhancement of telmisartan. AAPS Pharm Sci Tech 2012; 13(4): 1331-40.
[http://dx.doi.org/10.1208/s12249-012-9860-x] [PMID: 23054986]
[http://dx.doi.org/10.1208/s12249-012-9860-x] [PMID: 23054986]
[47]
Patel A, Dharamsi A. Nanocrystals- A Substantial Platform for Drug Delivery Applications. Curr Nanomed 2021; 11(4): 202-12.
[http://dx.doi.org/10.2174/2468187312666211221124154]
[http://dx.doi.org/10.2174/2468187312666211221124154]
[48]
Patil GB, Patil ND, Deshmukh PK, Patil PO, Bari SB. Nanostructured lipid carriers as a potential vehicle for Carvedilol delivery: Application of factorial design approach. Artif Cells Nanomed Biotechnol 2016; 44(1): 12-9.
[http://dx.doi.org/10.3109/21691401.2014.909820] [PMID: 24866725]
[http://dx.doi.org/10.3109/21691401.2014.909820] [PMID: 24866725]
[49]
Zhang W, Li X, Ye T, et al. Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology. Int J Pharm 2013; 454(1): 354-66.
[http://dx.doi.org/10.1016/j.ijpharm.2013.07.032] [PMID: 23876384]
[http://dx.doi.org/10.1016/j.ijpharm.2013.07.032] [PMID: 23876384]
[50]
Ling Tan JS, Roberts CJ, Billa N. Mucoadhesive chitosan-coated nanostructured lipid carriers for oral delivery of amphotericin B. Pharm Dev Technol 2019; 24(4): 504-12.
[http://dx.doi.org/10.1080/10837450.2018.1515225] [PMID: 30132723]
[http://dx.doi.org/10.1080/10837450.2018.1515225] [PMID: 30132723]
[51]
Journal AI, Marziyeh S, Moghddam M, Ahad A, Aqil M, Sarim S, et al. Optimization of nanostructured lipid carriers for topical delivery of nimesulide using Box - Behnken design approach. Artif Cells Nanomed Biotechnol 2016; 1401(4): 617-24.
[52]
Khan S, Shaharyar M, Fazil M, Baboota S, Ali J. Tacrolimus-loaded nanostructured lipid carriers for oral delivery - Optimization of production and characterization. Eur J Pharm Biopharm 2016; 108: 277-88.
[http://dx.doi.org/10.1016/j.ejpb.2016.07.017] [PMID: 27449630]
[http://dx.doi.org/10.1016/j.ejpb.2016.07.017] [PMID: 27449630]
Related Books
The Art of Nanomaterials
Advanced Materials and Nano Systems: Theory and Experiment - Part 2
Advanced Materials and Nano Systems: Theory and Experiment (Part-1)
Artificial Intelligence for Smart Cities and Villages: Advanced Technologies, Development, and Challenges
SILVER NANOPARTICLES: Synthesis, Functionalization and Applications
